Prospective studies integrating transcriptomic and spatial profiling approaches will be instrumental in clarifying this crosstalk and may inform rational therapeutic strategies targeting both tumour-intrinsic FGFR2 signalling and the TIME. The gene discussed is FGFR2; the disease is neoplasm.